指南与共识乳腺癌

2021圣加仑国际早期乳腺癌局部和全身治疗定制化共识指南

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.
指南 / 共识 · Ann Oncol · 2021-07-06

会议主题为「定制局部和全身治疗」,强调基于分期、生物学亚型、遗传因素、基因组特征、新辅助治疗反应及患者偏好等高度个体化临床特征来制定治疗推荐,需要多学科整合与动态调整。

要点

  • 早期乳腺癌治疗应基于分期、生物学亚型、遗传和基因组特征等个体化因素定制。
  • 新辅助治疗后的术前反应程度是制定后续治疗推荐的重要依据。
  • 定制化治疗需影像、病理、遗传、外科、内科和放疗等多学科动态整合。

核心结论

  • 早期乳腺癌的局部和全身治疗应基于高度个体化的临床特征进行定制。

主要发现

  • 会议主题为「定制局部和全身治疗」,讨论了早期乳腺癌诊断和治疗的多项关键问题。
  • 互动技术平台首次允许参会者直接向专家组成员提问并对关键小组问题投票。

临床怎么用

  • 临床决策应整合分期、生物学亚型、遗传因素、基因组特征、新辅助治疗反应和患者偏好等信息。
  • 治疗需在诊断时及治疗随访各步骤中根据积累的临床信息和治疗反应动态调整。

局限性

  • 会议以虚拟形式召开,摘要未报告共识推荐条款的具体数值或证据等级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this important bi-annual critical review of the 'state of the art' in the multidisciplinary care of early-stage breast cancer. Seventy-four expert panelists (see Appendix 1) from all continents discussed and commented on the previously elaborated consensus questions, as well as many key questions on early breast cancer diagnosis and treatment asked by the audience. The theme of this year's conference was 'Customizing local and systemic therapies.' A well-organized program of pre-recorded symposia, live panel discussions and real-time panel voting results drew a worldwide audience of thousands, reflecting the far-reaching impact of breast cancer on every continent. The interactive technology platform allowed, for the first time, audience members to ask direct questions to panelists, and to weigh in with their own vote on several key panel questions. A hallmark of this meeting was to focus on customized recommendations for treatment of early-stage breast cancer. There is increasing recognition that the care of a breast cancer patient depends on highly individualized clinical features, including the stage at presentation, the biological subset of breast cancer, the genetic factors that may underlie breast cancer risk, the genomic signatures that inform treatment recommendations, the extent of response before surgery in patients who receive neoadjuvant therapy, and patient preferences. This customized approach to treatment requires integration of clinical care between patients and radiology, pathology, genetics, and surgical, medical and radiation oncology providers. It also requires a dynamic response from clinicians as they encounter accumulating clinical information at the time of diagnosis and then serially with each step in the treatment plan and follow-up, reflecting patient experiences and treatment response.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021. PMID: 34242744. doi:10.1016/j.annonc.2021.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。